GRADE 3B FOLLICULAR LYMPHOMA
Clinical trials for GRADE 3B FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new GRADE 3B FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for GRADE 3B FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists test Triple-Threat immunotherapy to boost standard lymphoma treatment
Disease control Recruiting nowThis study is testing whether adding three new immunotherapy drugs (tafasitamab, retifanlimab, and rituximab) to standard chemotherapy is safe and effective for people newly diagnosed with aggressive B-cell lymphomas. The trial will enroll about 35 adults to see if this combinati…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
First patients to receive new Two-Pronged immune cell attack on lymphoma
Disease control Recruiting nowThis is a first-in-human study testing a new type of personalized immune cell therapy (CAR-T cells) for adults with Non-Hodgkin Lymphoma that has come back or stopped responding to standard treatments. The main goal is to find a safe dose of these modified immune cells, which are…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Scientists test double punch against Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is testing whether adding one of two new drugs (tazemetostat or zanubrutinib) to an existing two-drug therapy works better for controlling an aggressive type of blood cancer called large B-cell lymphoma. It is for adults whose cancer has returned or did not respond to …
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Scientists test 'Clean-Up' drugs to boost Cancer-Killing power of CAR T-Cell therapy
Disease control Recruiting nowThis study is for adults with aggressive B-cell lymphoma that has returned or not responded to prior treatments. After receiving a standard CAR T-cell therapy, patients whose cancer is still present but stable will be assigned to receive one of two additional drugs, both drugs, o…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC